Skip to content

Role of Nanoemulsified Sesame Oil in Post-operative Care After Endoscopic Sinus Surgery

Role of Nanoemulsified Sesame Oil in Post-operative Care After Endoscopic Sinus Surgery

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06437717
Enrollment
60
Registered
2024-05-31
Start date
2022-12-01
Completion date
2024-03-01
Last updated
2025-09-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Rhinosinusitis (Diagnosis)

Brief summary

The goal of our thesis is to design, develop and characterize a novel thermodynamically stable NE by spontaneous method intended for topical use. Subsequently, appraisal of nanoemulsified sesame oil formulation has been performed on the post-operative symptoms in CRS patients who have undergone ESS (endoscopic sinus surgery) combined with different types of nasal irrigation which may affect formulation efficacy.

Interventions

OTHERapplication of different topical nasal solutions

each group receives a type of nasal solution to detect if there is a difference in the outcomes in chronic rhinosinusitis patients

Sponsors

Mansoura University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

1. Patient age between 18 and 60 years old. 2. chronic rhinosinusitis patients who have undergone endoscopic sinus surgery.

Exclusion criteria

1. Patients with history of allergy for sesame seed derivatives. 2. Patients with chronic diseases which affecting the process of healing (uncontrolled DM, renal failure and hepatic failure). 3. Patients with nasal granulomas. 4. Patients with invasive fungal rhinosinusitis. 5. Smokers. 6. Patients with history of radio and/or chemotherapy exposure. 7. Patients with systemic diseases affecting integrity of nasal mucosa (e.g. CF, scleroderma, Sjogren syndrome …).

Design outcomes

Primary

MeasureTime frame
Sinonasal Outcome Test 22 (SNOT-22)weekly for three months
Lund-Kennedy endoscopic grading systemonce monthly for three months

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026